Phibro Animal Health Corporation (NASDAQ:PAHC) Declares Quarterly Dividend of $0.12

Phibro Animal Health Corporation (NASDAQ:PAHC) declared a quarterly dividend on Tuesday, July 28th. Investors of record on Wednesday, September 2nd will be paid a dividend of 0.12 per share on Wednesday, September 23rd. This represents a c) annualized dividend and a yield of 1.3%. The ex-dividend date is Wednesday, September 2nd.

Phibro Animal Health has a dividend payout ratio of 23.9% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Phibro Animal Health to earn $3.33 per share next year, which means the company should continue to be able to cover its $0.48 annual dividend with an expected future payout ratio of 14.4%.

Phibro Animal Health Price Performance

Phibro Animal Health stock traded up $0.17 during trading hours on Wednesday, hitting $36.54. 7,180 shares of the stock were exchanged, compared to its average volume of 309,567. The stock has a market capitalization of $1.48 billion, a P/E ratio of 15.74, a P/E/G ratio of 0.49 and a beta of 0.46. The business’s 50-day moving average is $32.52 and its two-hundred day moving average is $43.24. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.26 and a current ratio of 3.17. Phibro Animal Health has a 12 month low of $25.58 and a 12 month high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04. The company had revenue of $383.54 million during the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Equities research analysts expect that Phibro Animal Health will post 3.08 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Jack Bendheim sold 7,040 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $55.80, for a total value of $392,832.00. Following the completion of the transaction, the chief executive officer owned 67,720 shares in the company, valued at $3,778,776. The trade was a 9.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 18,608 shares of company stock valued at $983,825. Insiders own 50.13% of the company’s stock.

Institutional Investors Weigh In On Phibro Animal Health

Several hedge funds and other institutional investors have recently made changes to their positions in PAHC. KBC Group NV bought a new stake in shares of Phibro Animal Health during the first quarter worth $29,000. 1620 Investment Advisors Inc. boosted its holdings in Phibro Animal Health by 77.4% in the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after acquiring an additional 295 shares during the last quarter. Farther Finance Advisors LLC increased its position in Phibro Animal Health by 113.2% in the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after purchasing an additional 386 shares during the period. Rothschild Investment LLC increased its position in Phibro Animal Health by 2,500.0% in the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock worth $39,000 after purchasing an additional 1,000 shares during the period. Finally, iSAM Funds UK Ltd bought a new stake in Phibro Animal Health during the 3rd quarter worth about $61,000. 99.34% of the stock is owned by institutional investors and hedge funds.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.